---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-063514"
form_type: "8-K"
ticker: "SNDX"
cik: "0001395937"
company_name: "Syndax Pharmaceuticals Inc"
filed_at: "2025-05-05T23:59:59+00:00"
generated_at: "2026-05-22T16:54:39.283294+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Syndax Q1 Revuforj rev $20M, Niktimvo rev $13.6M; sNDA for mNPM1 AML

## Summary
- Revuforj net revenue $20.0M in first full quarter; Niktimvo net revenue $13.6M (Incyte reported) in first partial quarter.
- Submitted sNDA seeking Priority Review for revumenib in R/R mNPM1 AML under FDA RTOR program.
- Initiated EVOLVE-2 pivotal frontline trial of revumenib + venetoclax/azacitidine in mNPM1 and KMT2Ar AML.
- Net loss $84.8M ($0.98 per share) vs $72.4M ($0.85 per share) year ago; cash $602.1M.
- Full-year 2025 R&D guidance $260-280M, total R&D+SG&A $415-435M; expects to reach profitability.

## SEC filing metadata
- accession: 0000950170-25-063514
- form_type: 8-K
- ticker: SNDX
- cik: 0001395937
- company_name: Syndax Pharmaceuticals Inc
- filed_at: 2025-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1395937/000095017025063514/0000950170-25-063514-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1395937/000095017025063514/sndx-20250505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-063514
- JSON: https://secwatch.observer/filing/0000950170-25-063514.json
- Plain text: https://secwatch.observer/filing/0000950170-25-063514.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.